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Hydroxytyrosol (HT) plays a signiﬁcant role in cardiovascular disease (CVD) protection, and its metabolites are able to protect
from the endothelial dysfunction commonly present in atherosclerosis. This randomized double-blinded, placebo-controlled
crossover trial determined the eﬀect in healthy volunteers of two gastroresistant capsules containing 15mg/day of HT, for
a 3-week period (HTT). Evaluation of nutritional status, serum metabolites, oxidative stress biomarkers, and gene
expression of 9 genes related to oxidative stress, inﬂammation, and CVDs was performed. Oxidation biomarkers like thiol group
(p = 0 001), total antioxidant status (TAS) (p = 0 001), superoxide dismutase 1 (SOD1) (2−ΔΔCt = 3.7), and plasma concentration
of HT (2.83 μg·mL−1) were signiﬁcantly increased, while nitrite (p = 0 001), nitrate (p = 0 001), and malondialdehyde (MDA)
(p = 0 02) were drastically reduced after HTT. A signiﬁcant reduction of body fat mass percentage (p = 0 01), suprailiac
skinfold (p = 0 01), and weight (p = 0 04; Δ%=−0.46%) was observed after HTT. This study shows that regular intake of
15mg/day of HT changed body composition parameters and modulated the antioxidant proﬁle and the expression of
inﬂammation and oxidative stress-related genes. However, it is advisable to personalize HT doses in order to exert its
health beneﬁts in CVD prevention and protection of LDL-C particles from oxidative damage. This trial is registered with
ClinicalTrials.gov NCT01890070.
1. Introduction
Extra virgin olive oil (EVOO) is the main lipid component of
Mediterranean diet [1]. The Seven Countries Study, and
many other studies [2–4], demonstrated that Mediterranean
diet is able to reduce the incidence of chronic degenerative
diseases, while the PREDIMED study proved the eﬃcacy of
Mediterranean dietary program supplemented with olive oil
reduced the incidence of major cardiovascular events due to
several changes in pathways involved in cardiometabolic risk
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[5, 6]. EVOO’s ability to improve health conditions is due to
several components, like its high content of monounsatu-
rated fatty acids (MUFAs), in particular oleic acid, which is
able to improve α-linolenic acid (ALA) conversion in
longer-chain n-3 polyunsaturated fatty acids (PUFAs), lead-
ing to great health beneﬁts on cardiovascular diseases
(CDVs) [7]. The Food and Drug Administration (FDA)
had recognized olive oil (23 g/day) as a qualiﬁed health claim
to decrease the risk of coronary heart disease [8].
EVOO supplementation brings several beneﬁts on
CVDs, due to its antioxidant, anti-inﬂammatory, vasodila-
tory, and antiplatelet aggregation properties [9, 10]. How-
ever, the main EVOO cardioprotective eﬀect is attributable
to the presence of its phenolic compounds [11]. In fact,
European Food Safety Authority (EFSA) scientiﬁc opinion
has substantiated “health claims” related to speciﬁc EVOO
phenolic compounds. A daily amount of 5mg of hydroxy-
tyrosol (3,4 dihydroxyphenylethanol; 3,4-DHPEA or HT)
and its derivatives are responsible for the validated health
claim “protection of blood lipids from oxidative stress”
[12]. HT is the most abundant phenolic compound in
EVOO and plays a signiﬁcant role in CVD protection,
and its metabolites are able to protect from endothelial
dysfunction commonly present in atherosclerosis [13]. In
particular, HT is able to reduce hypercholesterolemia and
malondialdehyde (MDA) concentrations [14], inhibit per-
oxidation of low-density lipoprotein cholesterol (LDL-C)
[15], and increase high-density lipoprotein cholesterol
(HDL-C) [16, 17]. In vitro and in vivo studies demon-
strated that EVOO [18] and HT supplementation [19,
20] also improves antioxidant enzyme activity of superox-
ide dismutase 1 (SOD1), involved in the pathogenesis of
various diseases like atherosclerosis and hypertension
[21]. SOD1 is able to catalyze superoxide radical (O2
−) in
hydrogen peroxide (H2O2), which in turn is catalyzed into
water through glutathione peroxidase (GSH-Px) and cata-
lase (CAT) [21]. As well as SOD1, GSH-Px, and CAT,
several enzymes are involved in the regulation of oxidative
stress like macrophage migration inhibitory factor (MIF)
[22] and peroxisome proliferator-activated receptor
gamma (PPARγ) [23]. Conversely, reactive oxygen species
(ROS) have the ability to modulate the expression of
diﬀerent inﬂammation genes like nuclear factor of kappa
light polypeptide gene enhancer in B-cells (NFkB) and
consequently chemokine (C-C motif) ligand 2 (CCL2)
[24, 25]. A massive ROS amount, particularly radical
superoxide, could lead to the a reduction of nitric oxide
(NO) bioavailability, one of the main characteristics of
CVDs, due to increased peroxynitrite (ONOO−) produc-
tion [26], which seems to be inhibited by HT in vitro [27].
Based on the antioxidant eﬀects in dietary treatment with
EVOO or HT supplementation, we hypothesized that 3
weeks administration of 15mg/day of HT present in a new
formulation, with intestinal release, could lead to a change
in nutritional status. The ﬁrst endpoint of this study was to
evaluate the body composition parameter changes; the
secondary endpoint was to verify the antioxidant status and
the glucose and lipid proﬁle. The third endpoint was the eval-
uation of HT antioxidant eﬀect on gene expression of
selected genes belonging to inﬂammatory and oxidative
stress pathways. Therefore, a randomized clinical trial was
performed on healthy volunteers in a free dietary regimen.
2. Methods
2.1. Study Design and Subjects. The study was conducted
using a double-blinded, randomized, placebo-controlled
crossover design, between December 2015 and April 2016.
Forty subjects were recruited sequentially within a rou-
tine medical checkup program at the Section of Clinical
Nutrition and Nutrigenomics, Department of Biomedicine
and Prevention of the University of Rome Tor Vergata, and
twelve of them were excluded from the trial (four subjects
did not meet the inclusion criteria, while eight subjects
declined to participate). Finally, twenty-eight patients who
were between 18 and 65 years old and had a body mass index
(BMI) between 18.5 and 29.9 kg/m2 respected the inclusion
criteria and completed the trial. Due to the diﬀerent pheno-
types of obesity, according to De Lorenzo et al. [28], we
selected as eligible for the study only healthy subjects that
belong to the normal or overweight range of BMI (18.5
and 29.9 kg/m2; total body fata mass percentage (TBFat%)
< 30% for women and <25% for men) and subjects who are
classiﬁed as metabolically healthy obese (TBFat% > 30% for
women and >25% for men), without metabolic complica-
tions. Eligible patients were randomly divided in two groups
(1 : 1 ratio) and took daily note 2 capsules of 7.5mg/capsule
of HT, or n.2 capsules of placebo. HT capsules were adminis-
trated 1 time/day, 2 h before lunch in order to ensure gastric
transit and intestinal absorption. According to EFSA scien-
tiﬁc opinion, we have established to administer 15mg/die
of HT in order to guarantee the achievement of the HT por-
tion set by the authority. A person not involved in the clinical
trial carried out the randomization. The study consists of 3
weeks chronic treatment with HT (HTT) or placebo (PT),
to ensure complete adhesion of healthy volunteers to the pro-
tocol separated by a - week washout period, resulting in a
total duration of 8 weeks. At the end of washout, the groups
received the other treatment for the same period (Figure 1).
At the beginning and at the end of each treatment, body com-
position evaluation, gene expression, and blood analysis were
performed. Subjects were asked to maintain their usual life-
style habits and to report any illness or abnormality arising
during the study.
The primary outcome of this study was the evaluation of
nutritional status according body composition changes
measured by anthropometry, plicometry, and bioimpeden-
tiometry (BIA), after HTT. The secondary outcome was to
asses a panel of blood analysis, on antioxidant status (total
antioxidant status (TAS) and lipid peroxidation, expressed
as MDA, thiols, nitrites/nitrates), glucose and lipid proﬁle
(TC, high-density lipoprotein cholesterol (HDL-C), low-
density lipoprotein cholesterol (LDL-C), and triglycerides
(Tg)), and plasma and erythrocytes membrane PUFAs.
The third outcome was the evaluation of antioxidant
eﬀect of HTT on gene expression of selected genes belonging
to inﬂammatory and oxidative stress pathways: MIF, SOD1,
PPARγ, CAT, CCL2, NFkB1, methylenetetrahydrofolate
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reductase (MTHFR), apolipoprotein E (APOE), and angio-
tensin I-converting enzyme (ACE).
All participants recruited in the study authorized their
participation by reading and signing the informed consent,
conducted in accordance with the provisions of the Ethics
Committee of Medicine, University of Rome Tor Vergata
and with the Helsinki Declaration of 1975 as revised in 1983.
Trial registration: NCT01890070.
2.2. Exclusion Criteria. The exclusion criteria are as follows:
pregnancy; breast-feeding; type 1 and type 2 diabetes; heart
failure; endocrine disorders; liver dysfunction; liver, kidney,
autoimmune, chronic viral (hepatitis C and B, HIV), and
neoplastic diseases; corticosteroid and chronic inﬂammatory
therapy; and participation in other dietary trials.
2.3. Sample Size. Insulin value was selected as a parameter
to calculate minimum sample size according to de Bock
et al. [29]. The minimum sample size was calculated using
a two-tailed one-sample Student’s t-test, considering the
following: (i) insulin to be detected between baseline and
HTT |δ|≥ 15 μU/mL—1; (ii) SD of the paired diﬀerences,
SD=15μU/mL; and (iii) type I error probability α=0.05
and power 1−β=0.90. The result was a minimum sample
size of 10 per group.
2.4. HT and Placebo Capsule Composition. HT capsules were
composed of the following: hard gelatin enteric coated
capsules (Fenolia™, P&P Farma Srl, Turin, Italy) at 7.5mg
strength of hydroxytyrosol from olive extract (elaVida™,
DSM, Heerlen, The Netherlands) in extra virgin organic olive
oil vehicle and enteric coated with Eudraguard® natural
(Evonik Industries AG, Essen, Germany). Placebo capsule
formulation was of the same sample formulation (HT
capsules) but without the elaVida extract.
2.5. Anthropometric, Bioimpendance Analysis, and Dual-
Energy X-Ray Absorptiometry. Waist and hip circumfer-
ences were taken using a ﬂexible steel metric tape to the
nearest 0.5 cm, according to International Society for the
Advancement of Kin anthropometry protocol and
National Institute of Health Guidelines. Body weight (kg)
was measured to the nearest 0.1 kg, using a technical
balance (Invernizzi, Rome, Italy). Waist/hip ratio (WHR)
was also evaluated in relation to clinical risk thresholds,
that is, WHR> 1 for men and WHR> 0.9 for women.
Height (m) was measured to the nearest 0.1 cm using a
stadiometer (Invernizzi, Rome, Italy) [30]. BMI was
calculated using the formula BMI=body weight/height2
(kg/m2). Body composition analysis was assessed by BIA
phase sensitive system (BIA 101S, Akern/RJL Systems,
Florence, Italy) [31], and total body fat mass (TBFat)
and total body lean mass (TBLean) were assessed using a
dual-energy X-ray absorptiometry (DXA) (i-DXA, GE
Medical Systems, Milwaukee, WI, USA) according to the
previously described procedures [26, 32].
Fat mass (FM) distribution was determined using a
plicometer (Harpenden Callipers) with skinfold measure-
ment in triplicate and collected at four points: triceps, biceps,
subscapular, and suprailiac. Skinfold measurements were uti-
lized in Durnin andWomersley’s equations to calculate body
density, and the Siri formula was subsequently applied to
predict FM [33].
2.6. Dietary Assessments. Before the beginning of the clinical
trial, a validated and adapted dietary questionnaire was self-
administered [34]. The food intake before and during the
clinical trial was assessed from 3-day diet records completed
for two weekdays and one weekend day [35]. The subjects
were instructed by a dietitian to record weight and/or mea-
sures of all foods and beverages consumed, to use product
brand names when recording dietary intake. Photographs
of food portion sizes were provided to help estimate the
amount of food consumption. Diet records were reviewed
as they were turned in to conﬁrm that all written food items
were legible and to clarify the amounts of foods consumed.
The estimated intake of macronutrients was calculated by
using the software Dietosystem®.
2.7. Analysis of Blood Samples
2.7.1. Biochemical Analysis. Blood samples were taken after a
12-hour overnight fast. Blood samples were collected in ster-
ile tubes containing EDTA (Vacutainer®) and placed on ice.
Plasma was separated by centrifugation (1600 rpm, at 4°C
for 10min), removed, aliquoted, and stored at −80°C. All
clinical chemistry analyses, except plasma glucose and serum
lipid analysis, were carried out using an ADVIA®1800
Chemistry System (Siemens Healthcare) following standard
procedures [36]. Plasma glucose concentrations were mea-
sured using the glucose oxidase method and automated
glucose analyzer (COBAS INTEGRA 400, Roche Diagnos-
tics, Indianapolis, IN, USA); serum lipid proﬁle components
were determined by standard enzymatic colorimetric
techniques (Roche143 Modular P800, Roche Diagnostics,
Indianapolis, IN, USA). Cardiovascular risk was determined
by the following ratios: TC/HDL-C (<3) and LDL-C/HDL-
Enrollment
HTT PT
PT HTT
3 weeks
chronic
treatment
3 weeks
chronic
treatment
Washout
2 weeks
E T0 T1 T2 T3
Figure 1: Study design. Clinical trial design: HTT, 15mg/day hydroxytyrosol treatment; PT, placebo treatment.
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C (<2). Adipocyte dysfunction was evaluated by the lipid
accumulation product index (LAP) calculated using the
following formulas:
Waist circumference cm – 65
× Tg concentration mM formen,
Waist circumference cm – 58
× Tg concentration mM for women
1
Atherogenic Index of Plasma (AIP) was determined
using the following formula:
Log Tg concentration mg/dLHDL − C mg/dL 2
All the analyses were performed in duplicate, while the
measurements were performed in triplicate.
2.7.2. Antioxidant Status. Total antioxidant status (TAS) and
lipid peroxidation (expressed as MDA, thiols, and nitrites/
nitrates) were determined using commercially available kits
following the manufacturer’s instructions. Fluorometric thiol
assay kit (MAK151-1KT), MDA assay kit (MAK085-1KT),
and nitrite/nitrate assay kit (23479-1KT-F) were purchased
from Sigma-Aldrich (Milan, Italy). Total antioxidant status
assay kit (615700-1KIT) was purchased from Merck
Millipore (Milan, Italy). Oxidized LDL-C (ox-LDL) concen-
tration in plasma was measured by enzyme-linked immuno-
sorbent assay using the mAb-4E6 antibody (Mercodia AB,
Uppsala, Sweden).
Total plasma and cell membrane PUFAs were analyzed
from venous blood sample and collected in tubes containing
EDTA (Vacutainer) and centrifuged (3500 rpm for 5min).
Plasma was removed and stored at −80°C while red cells were
washed with saline solution (NaCl 0.9%), collected, and
freezed at −80°C. Erythrocyte membrane PUFAs methyl
esters were extracted by a modiﬁed version of previously
reported methods [37]. In plasma, total PUFA methyl esters
were evaluated through gas chromatography (GC, model
6890N, Agilent Technologies Italia Spa), coupled to a mass
spectrometric detector (MSD, model Agilent 5973 inert, Agi-
lent Technologies Italia Spa). Chromatographic separation
was performed on a BPX-70 (70% cyanopropyl polysilpheny-
lensiloxane, SGE Analytical Science, Austin, TX, USA) 30m
capillary column (0.25mm ID, 0.25μm ﬁlm thickness). All
the analyses were performed in triplicate.
2.8. Sample Collection, RNA Extraction, and Analysis. Blood
samples were collected, stabilized in PAX gene blood RNA
tubes (Pre AnalytiX Qiagen, Hombrechtikon, Switzerland),
and stored at −80°C. Total RNA of each collected sample
was puriﬁed with PAX gene blood miRNA kit following
the manufacturer’s instructions (Pre Analytix Qiagen,
Hombrechtikon, Switzerland). Total RNA was quantiﬁed
and assessed for quality by spectrophotometry (Nanodrop,
Wilmington, USA) and agarose gel electrophoresis. Spe-
ciﬁc RT2 proﬁler PCR arrays (Qiagen, Netherlands) were
used for human oxidative stress (PAHS-065ZA, Qiagen,
Netherlands) and human inﬂammation (PAHS-097ZA,
Qiagen, Netherlands) pathways. Gene expression of the fol-
lowing 9 genes was analyzed: MIF (GenBank accession note
AF469046.1), SOD1 (GenBank accession note AK312116.1),
PPARγ (GenBank accession note AB307692.1), CAT
(GenBank accession note AY545477.1), CCL2 (GenBank
accession note AK311960.1), NFkB1 (GenBank accession
note AK1122850.1), methylenetetrahydrofolate reductase
(MTHFR) (GenBank accession note AB209113.1),
apolipoprotein E (APOE) (GenBank accession note
K314898.1), and angiotensin I-converting enzyme (ACE)
(GenBank accession note AB208971.1). Each qRT-PCR
experiment was performed in triplicate and repeated at
least twice, in line with the manufacturer’s instructions
(Qiagen, Netherlands).
2.9. HT Bioavailability Determination. HT was extracted
from acidiﬁed plasma by solid-phase extraction using an
Oasis HLB 1 cc vacuum cartridge 30mg, 30μm (Waters,
Italy) according to Ruiz-Gutiérrez et al. [38]. The analytical
evaluation was performed following Miralles et al. [39] with
some modiﬁcations using an Agilent HPLC system (1100
series) coupled with a DAD detection and equipped with an
autosampler refrigerated at 4°C. The elution gradient con-
sisted of mobile phase (A) H2O (0.2% CH3COOH, pH 3.1)
and (B) CH3OH. HT was recognized and quantiﬁed at
280 nm based on the supplier’s standard, comparing reten-
tion time and relative UV-vis spectra (range 200–400nm).
A 500μg·mL−1 HT standard stock solution was prepared
using acetic acid 0.2% and methanol 75/25 (v/v) (pH 3.30).
From this solution, freshly working standard solutions from
3 to 100μg·mL−1 were prepared. HT≥ 98% were purchased
from Sigma-Aldrich (Milan, Italy). Glacial acetic acid, phos-
phoric acid, and methanol were HPLC grade and purchased
from Merck (Darmstadt, Germany). All the analysis were
performed in triplicate.
2.10. Statistical Analysis. Statistical analysis was carried out
using IBM SPSS 21.0 for Windows (IBM Corp., Armonk,
NY, USA). After the Shapiro-Wilk test, a paired t-test or a
nonparametric Wilcoxon test was performed to evaluate
diﬀerences before and after HTT. In all statistical tests
performed, the null hypothesis (no eﬀect) was rejected at
the 0.05 level of probability.
Correlation was performed using a parametric (Pearson)
or nonparametric test (Spearman’s rank correlation).
Data analysis of quantitative real-time PCR: the value
used to plot relative gene expression was determined
using the expression fold change (FC) =2−ΔΔCt, using β-
actin (ACTB) as housekeeping gene. Only genes with a
FC> 2 were selected and referred to as “diﬀerentially
expressed genes,” with a p value < 0.05 taken to indicate
statistical signiﬁcance.
A test for carry-over eﬀects according to Kenward and
Jones [40] was applied. No carry-over eﬀects between the
two treatment periods could be observed. All analyses
are presented on a per-protocol basis. Of the 40 partici-
pants enrolled, 28 subjects concluded the study and for
these, complete data sets were available.
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3. Results
3.1. Subjects Characteristics. Of the forty subjects enrolled,
twelve of them were excluded from the trial (four subjects
did not meet the inclusion criteria, while eight subjects
declined to participate). Finally, twenty-eight patients com-
pleted the trial (Figure 1). Any changes to trial outcomes after
the trial commenced occurred. The average age of subjects
was 32.00± 12.22 years, where 57.1% were female and
42.9% were male (Table 1). The sample divided for sex pre-
sented diﬀerences for the following parameters: height,
waist/hip circumference ratio, TBW, ICW, ECW, TBFat%,
TBLean (kg), triceps, and FM% skinfold (p = 0 001); biceps
skinfold (p = 0 01); sovrailiac skinfold, phase angle, and
TBFat (kg) (p = 0 05). No changes for bioclinical analysis
were observed. The sample divided for age presented
Table 1: Enrollment clinical and anthropometric characteristics of healthy volunteers.
Parameter Frequency
(n = 28) (n; %)
Gender
Male (n = 12; 42.9%)
Female (n = 16; 57.1%)
Body composition phenotype
NWL (n = 12; 42.9%)
MHO (n = 16; 57.1%)
Mean± SD Median (min–max)
(n = 28) (n = 28)
Age (years) 32.00± 12.22 27.00 (23.00–64.00)
SBP (mmHg) 119.31± 7.79 120.00 (100.00–130.00)
DBP (mmHg) 74.46± 6.65 76.00 (60.00–80.00)
TC (mg/dL) 156.54± 14.36 160.00 (138.00–184.00)
HDL-C (mg/dL) 61.92± 4.57 63.00 (54.00–69.00)
LDL-C (mg/dL) 88.69± 13.23 86.00 (63.00–110.00)
Tg (mg/dL) 67.77± 32.46 58.00 (32.00–134.00)
Glycemia (mg/dL) 72.46± 5.62 72.00 (62.00–79.00)
Insulin (μU/mL) 7.58± 4.09 6.81 (3.32–17.68)
Height (cm) 165.68± 9.29 163.80 (151.50–183.60)
Weight (kg) 66.61± 10.06 69.00 (51.10–80.90)
BMI (kg/m2) 23.62± 2.47 23.46 (20.20–28.00)
Waist circumference (cm) 76.15± 6.97 76.80 (66.00–90.40)
Hip circumference (cm) 99.12± 8.04 97.90 (89.00–116.00)
Waist/hip ratio 0.77± 0.06 0.77 (0.69–0.91)
Biceps skinfold (mm) 7.21± 4.37 6.90 (2.20–15.13)
Triceps skinfold (mm) 16.68± 6.61 16.80 (7.40–26.50)
Subscapular skinfold (mm) 13.55± 4.67 13.80 (6.50–21.90)
Suprailiac skinfold (mm) 12.26± 6.14 9.87 (5.40–25.60)
FM% (skinfolds) 24.92± 8.08 27.29 (12.74–39.05)
TBW (L) 36.13± 6.76 34.00 (27.90–46.40)
ECW (L) 16.81± 2.76 15.80 (12.50–21.60)
ICW (L) 19.31± 4.40 18.20 (13.20–26.40)
Phase angle 5.81± 0.78 5.80 (4.40–7.00)
TBFat% (DXA) 28.26± 10.43 30.00 (11.10–44.90)
TBFat (kg) 18.60± 7.84 16.64 (7.84–36.13)
TBLean (kg) 45.14± 10.80 42.45 (30.99–62.62)
Energy intake (kcal) 1717.48± 546.09 1750.32 (1107.20–2585.01)
Carbohydrates (g) 245.89± 80.09 234.82 (152.79–413.19)
Protein (g) 76.30± 19.95 76.79 (47.37–119.97)
Lipids (g) 54.11± 26.41 42.94 (18.78–95.88)
All results were expressed as mean ± standard deviation (SD) (number of replicates = 3) and median (minimum and maximum). SBP: systolic blood pressure;
DBP: diastolic blood pressure; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; Tg: triglycerides;
BMI: body mass index; FM: fat mass; TBW: total body water; ECW: extracellular water; ICW: intracellular water; TBFat: total body fat; TBLean: total body lean.
5Oxidative Medicine and Cellular Longevity
diﬀerences for the following parameters: waist/hip circumfer-
ences ratio and ECW (p = 0 001); waist circumference and
TBW (p = 0 01); height (p = 0 02); TBLean (kg) (p = 0 03);
diastolic blood pressure (DBP) and Tg (p = 0 04); and
weight (p = 0 05). No changes for other bioclinical analysis
were observed.
According to the dietary questionnaires, 78.6% and
85.7% of subjects presented an adequate food frequency
and food habits, respectively, at the same time 21.4% and
14.3% of subjects presented a discrete food frequency and
food habits.
3.2. Food Intake Analysis. Concerning food intake analysis,
there were not signiﬁcant diﬀerences between HTT and
PT. Total energy intake were 1925.33 kcal and 1602.57 kcal
(p = 0 44) during HTT and PT, respectively. Carbohydrate
intake was 250.46 g and 225.64 g (p = 0 67), protein
intake was 76.04 g and 72.20 g (p = 0 58), and lipid con-
sumption was 69.60 g and 45.70 g (p = 0 21) during HTT
and PT, respectively.
3.3. Biochemical Data. After HTT, a signiﬁcant decrease in
nitrite (p = 0 001), nitrate (p = 0 001), and MDA (p = 0 02),
as well as an increase in thiol groups (p = 0 001) and
TAS values (p = 0 001) (Table 2), were obtained. These
results matched the signiﬁcant increase in HT bioavail-
ability (2.83 μg·mL−1; min–max: 2.25–3.50). No signiﬁcant
changes were observed in ox-LDL-C concentration (Table 2).
Moreover, no signiﬁcant changes were observed after HTT
in Tg, TC, and HDL-C (Table 2), as well as in plasma
Table 3: Plasmatic and erythrocyte membrane PUFA concentrations after HTT and PT.
PUFAs Parameter
Baseline (T0) HTT p Baseline (T2) PT p
Mean± SD
(n = 28)
Mean± SD
(n = 28)
Mean± SD
(n = 28)
Mean± SD
(n = 28)
Plasmatic AA/EPA 24.33± 29.51 21.47± 20.15 0.40 19.18± 29.15 17.39± 14.44 0.71
Plasmatic AA/DHA 2.28± 0.77 2.43± 0.70 0.06 2.29± 0.62 2.46± 0.83 0.22
Erythrocytes membrane AA/EPA 60.60± 87.20 54.24± 76.75 0.12 51.60± 74.65 50.26± 63.03 0.77
Erythrocytes membrane AA/DHA 3.51± 0.87 3.39± 0.78 0.07 3.40± 0.81 3.46± 0.99 0.56
All parameters were evaluated before and after HTT. All results were expressed as mean ± standard deviation (SD) (number of replicates = 3). PT: placebo
treatment; HTT: 15mg/day hydroxytyrosol treatment; AA: arachidonic acid; EPA: eicosapentaenoic acid; DHA: docosahexaenoic acid.
Table 2: Biochemical analysis.
Parameter
Baseline (T0)
Mean± SD
(n = 28)
HTT
Mean± SD
(n = 28)
p
Baseline (T2)
Mean± SD
(n = 28)
PT
Mean± SD
(n = 28)
p
TC (mg/dL) 155.79± 12.19 163.07± 18.74 0.11 161.71± 18.79 167.75± 16.20 0.06
HDL-C (mg/dL) 61.14± 9.43 62.21± 7.75 0.64 64.18± 7.85 64.31± 9.19 0.49
Tg (mg/dL) 64.57± 29.92 60.71± 22.04 0.30 71.18± 38.02 81.25± 56.74 0.65
LDL-C (mg/dL) 88.14± 10.60 93.71± 16.38 0.02∗ 90.82± 14.83 95.06± 13.39 0.01∗
Glycemia (mg/dL) 79.86± 8.70 77.21± 8.67 0.43 80.1± 6.70 76.23± 7.77 0.43
Insulin (μU/mL) 6.51± 3.00 6.78± 2.79 0.52 6.26± 2.88 6.48± 2.34 0.41
oxLDL-C (U/L) 40.18± 6.66 41.32± 6.63 0.52 40.98± 9.75 44.11± 9.32 0.24
TC/HDL-C 2.59± 0.35 2.65± 0.42 0.97 2.28± 0.39 2.06± 0.44 0.08
TC/LDL-C 1.78± 0.19 1.76± 0.17 0.59 1.98± 0.29 1.96± 0.17 0.23
LAP 10.64± 3.70 11.21± 4.44 0.36 10.56± 3.80 10.27± 3.46 0.22
AIP −0.01± 0.22 −0.04± 0.19 0.45 −0.01± 0.14 −0.01± 0.18 0.99
Thiols (μM) 23.04± 2.90 27.06± 2.51§ 0.001∗ 22.90± 2.54 23.45± 2.08 0.32
Nitrites (μM) 6.90± 3.17 2.77± 1.86§ 0.001∗ 6.59± 2.97 5.87± 1.79 0.56
Nitrates (μM) 76.72± 60.89 46.04± 20.00a,§ 0.001∗ 75.84± 58.63 72.05± 61.00a 0.77
MDA (μM) 0.44± 0.27 0.26± 0.23a,∗ 0.02∗ 0.49± 0.12 0.45± 0.33a 0.92
All parameters were evaluated before and after HTT. All results were expressed as mean ± standard deviation (SD) (number of replicates = 3). Statistical
signiﬁcance attributed to results with ∗p < 0 05 (between HTT and baseline (T0) or between PT and baseline (T2)) and §P < 0 01 (between HTT and
baseline (T0) or between PT and baseline (T2)) after parametric test (Student t-test) or anonparametric test (Wilcoxon-Mann–Whitney). HTT: 15mg/day
hydroxytyrosol treatment; PT: placebo treatment; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; Tg: triglycerides; LDL-C: low-density
lipoprotein cholesterol; TAS: total antioxidant status; oxLDL-C: oxidized low-density lipoprotein; LAP: lipid accumulation product; AIP: atherogenic index
of plasma; MDA: malondialdehyde.
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Table 4
(a) Bioclinical and gene expression analysis at Baseline
Baseline
Glycemia
(mg/dL)
Insulin
(U/mL)
TC
(mg/dL)
HDL-C
(mg/dL)
Tg
(mg/dL)
LDL-C
(mg/dL)
TAS
(mM)
Thiols
(μM)
Nitrites
(μM)
Nitrates
(μM)
MDA
(μM)
SOD1
Glycemia
(mg/dL)
ρ −0.37 −0.33 −0.56 −0.45 0.54 0.52 −0.59 0.33 0.21 0.58 −0.20
p 0.42 0.47 0.19 0.31 0.21 0.24 0.16 0.47 0.64 0.17 0.66
Insulin
(U/mL)
ρ −0.08 −0.30 0.67 −0.26 −0.61 0.14 0.46 −0.34 0.23 −0.15
p 0.86 0.51 0.10 0.57 0.15 0.76 0.30 0.46 0.62 0.75
TC
(mg/dL)
ρ 0.52 0.17 0.55 −0.21 0.59 −0.21 −0.26 −0.40 −0.10
p 0.23 0.71 0.20 0.65 0.26 0.65 0.58 0.38 0.83
HDL-C
(mg/dL)
ρ −0.29 −0.13 0.21 0.34 −0.61 0.01 −0.49 0.28
p 0.52 0.78 0.65 0.45 0.14 0.98 0.26 0.54
Tg
(mg/dL)
ρ −0.25 −0.99 0.65 0.39 −0.19 0.14 −0.35
p 0.59 0.001∗ 0.11 0.39 0.68 0.77 0.45
LDL-C
(mg/dL)
ρ 0.26 0.13 0.001 −0.31 −0.03 −0.04
p 0.57 0.79 0.99 0.50 0.94 0.93
TAS
(mM)
ρ −0.71 −0.25 0.26 −0.04 0.24
p 0.07 0.59 0.58 0.94 0.61
Thiols
(μM)
ρ −0.15 −0.28 −0.35 −0.13
p 0.76 0.55 0.44 0.78
Nitrites
(μM)
ρ 0.49 0.76 −0.87
p 0.26 0.05∗ 0.01∗
Nitrates
(μM)
ρ 0.43 −0.70
p 0.34 0.08
MDA
(μM)
ρ −0.61
p 0.14
Analysis was conducted using Pearson or Spearman’s rank correlation coeﬃcient ρ. Statistical signiﬁcance attributed to results with ∗p < 0 05. TC: total
cholesterol; HDL-C: high-density lipoprotein cholesterol; Tg: triglycerides; LDL-C: low-density lipoprotein cholesterol; TAS: total antioxidant status;
SOD1: superoxide dismutase 1.
(b) Bioclinical and gene expression analysis after HTT
HTT
Glycemia
(mg/dL)
Insulin
(U/mL)
TC
(mg/dL)
HDL-C
(mg/dL)
Tg
(mg/dL)
LDL-C
(mg/dL)
HT
(mg/mL)
TAS
(mM)
Thiols
(μM)
Nitrites
(μM)
Nitrates
(μM)
MDA
(μM)
SOD1
Glycemia
(mg/dL)
ρ −0.46 0.54 −0.68 −0.64 0.73 −0.11 0.64 −0.32 0.41 −0.43 0.14 −0.36
p 0.29 0.21 0.09 0.12 0.07 0.81 0.12 0.48 0.36 0.34 0.77 0.43
Insulin
(U/mL)
ρ −0.10 −0.02 0.58 −0.16 0.53 −0.51 −0.25 0.15 0.65 −0.13 0.32
p 0.83 0.97 0.17 0.73 0.22 0.25 0.59 0.76 0.11 0.78 0.48
TC
(mg/dL)
ρ −0.07 −0.02 0.94 0.44 −0.04 −0.13 0.68 −0.71 −0.02 −0.29
p 0.88 0.96 0.001∗ 0.32 0.94 0.78 0.09 0.07 0.97 0.53
HDL-C
(mg/dL)
ρ 0.23 −0.39 0.17 −0.32 0.32 −0.15 −0.17 −0.25 0.21
p 0.62 0.39 0.71 0.48 0.48 0.75 0.72 0.59 0.65
Tg
(mg/dL)
ρ −0.08 0.41 −0.98 0.46 0.08 0.19 −0.35 −0.05
p 0.87 0.37 0.001∗ 0.30 0.86 0.69 0.44 0.92
LDL-C
(mg/dL)
ρ 0.36 0.06 −0.10 0.71 −0.67 0.01 −0.45
p 0.43 0.90 0.82 0.07 0.10 0.99 0.31
HT
(mg/mL)
ρ −0.34 0.26 0.84 −0.17 −0.47 −0.46
p 0.45 0.57 0.02∗ 0.71 0.29 0.30
TAS
(mM)
ρ −0.44 −0.03 −0.12 0.37 −0.02
p 0.32 0.94 0.79 0.42 0.97
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arachidonic acid (AA)/eicosapentaenoic acid (EPA) and AA/
docosahexaenoic (DHA) ratios, PUFAs erythrocytes mem-
brane, and plasma concentrations (Table 3). After HTT, a
positive correlation between TC and LDL-C was observed
(ρ = 0 94; p = 0 001) (Table 4(b). Furthermore, a positive
correlation between nitrite and HT bioavailability (ρ = 0 84;
p = 0 02) was observed after HTT (Table 4(b)). On the
other hand, a signiﬁcant positive correlation between
MDA and nitrite concentration (ρ = 0 76; p = 0 04) at
baseline was observed. This correlation was not kept after
treatment (Table 4(a)).
3.4. Gene Expression Data. Signiﬁcant upregulation of SOD1,
with a fold change exceeding the threshold set at 2, was
observed (2−ΔΔCt = 3.7) after HTT (Figure 2). At baseline
(T0), correlation analysis showed a signiﬁcant negative
correlation (ρ = −0 87; p = 0 01) between SOD1 gene expres-
sion (2−ΔCt = 0.01) and the concentration of circulating
nitrites (Table 3). No other signiﬁcant gene expression
changes were observed.
3.5. Body Composition Data. After HTT, a signiﬁcant reduc-
tion in weight (p = 0 04; Δ%=−0.46%), FM% (p = 0 01;
Δ%=−3.52%) and suprailiac skinfold (p = 0 01; Δ%=
−6.1%) were observed. BIA showed a signiﬁcant increase
in phase angle both in HTT (p = 0 01; Δ%=7.23%) and
PT (p = 0 02; Δ%=−2.45%) in reduction of extracellular
water (ECW) for both treatments (HTT: p = 0 001; Δ%=
−5.44%; PT: p = 0 02; Δ%=1.69%) (Table 5).
4. Discussion
EVOO, used in the traditional Mediterranean diet, contains
phenolic compounds that have several beneﬁcial eﬀects on
lipoproteins, inﬂammatory markers, oxidative damage, cellu-
lar and platelet functions, bone integrity, and antimicrobial
activity [41–43]. Moreover, food industries have manifested
great interest in polyphenol bioavailability and in “functional
food” based on speciﬁc polyphenol content [44, 45]. The
EFSA established for the EVOO polyphenol the health claim
“protection of blood lipids from oxidative stress.” This health
claim is valid only if the daily intake of HT and its derivatives
is at least 5mg/die, in order to have a protection of LDL
particles from oxidative damage [12]. In the present study,
the administration of 15mg/die of HT was established in
order to guarantee the achievement of recommended dose.
HT antioxidant activity is related to the high bioavailabil-
ity and elevated absorption capacity found to be essential for
pharmacokinetic properties. A stable resonance structure is
produced by the catecholic structure of HT, which is able to
scavenge the peroxyl radicals and interrupt a peroxidative
chain reaction [16]. Compared to intravenous administra-
tion, the ingestion of HT, conveyed in EVOO, is more eﬀec-
tive in terms of bioavailability [46].
Vissers et al. [47] demonstrated that healthy volunteers
and ileostomy patients absorb EVOO polyphenols equally,
concluding that most phenols ingested are absorbed by the
small intestine. In our study, plasma HT concentration
showed a signiﬁcant increase after intervention. We
observed the presence of 2.83 μg·mL−1 of HT in plasma
proving that the gastroresistant formulation adopted allows
the HT, as well as other EVOO polyphenols, to be released
in the intestine without suﬀering degradation in the stomach
and showing that the type of vehicle used allowed the HT to
remain for a longer period in the plasma compartment.
The sample divided for sex presented some signiﬁcant
diﬀerences for height and body composition parameters, at
the same time the sample divided for age presented signiﬁ-
cant diﬀerences for height, body composition parameters,
and DBP and Tg concentrations. However, parameters which
resulted diﬀerent in the analysis are perfectly in line with
physiological diﬀerences between males and females and
physiological adaptation for diﬀerent age [48–50].
In line with Anderson-Vasquez et al. [51], we observed a
signiﬁcant reduction in weight and suprailiac skinfold and
FM% after HTT. FM accumulation could lead to several
metabolic changes which incremented CVD risk [52]. The
endocrine role of adipose tissue, with the related release of
inﬂammatory cytokines, reduces the oxidative damage
response and at the same time increases oxidative stress [53].
Body weight and TBFat reduction determines the improve-
ment of the response to oxidative processes. In as much as
body weight reduction was observed only after HTT in a free
dietary regimen, without signiﬁcant changes in energy intake
Table 4: Continued.
HTT
Glycemia
(mg/dL)
Insulin
(U/mL)
TC
(mg/dL)
HDL-C
(mg/dL)
Tg
(mg/dL)
LDL-C
(mg/dL)
HT
(mg/mL)
TAS
(mM)
Thiols
(μM)
Nitrites
(μM)
Nitrates
(μM)
MDA
(μM)
SOD1
Thiols
(μM)
ρ 0.22 −0.34 −0.57 −0.70
p 0.64 0.46 0.18 0.08
Nitrites
(μM)
ρ −0.46 −0.47 −0.71
p 0.30 0.28 0.07
Nitrates
(μM)
ρ −0.02 0.56
p 0.96 0.19
MDA
(μM)
Ρ 0.46
p 0.30
Analysis was conducted using Pearson or Spearman’s rank correlation coeﬃcient ρ. Statistical signiﬁcance attributed to results with ∗p < 0 05. HTT:
hydroxytyrosol treatment; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; Tg: triglycerides; LDL-C: low-density lipoprotein cholesterol;
TAS: total antioxidant status; SOD1: superoxide dismutase 1.
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during all the time of the study, the antioxidant eﬀect is
dependent on HTT, in a vicious cycle. At the same time, we
reported a signiﬁcant increase in phase angle, with a substan-
tial reduction in ECW in liters during both HTT and PT,
results that are not attributable to a speciﬁc treatment.
This study has highlighted the signiﬁcant eﬀect of a daily
intake of 15mg/day HT supplementation compared to pla-
cebo on oxidation markers, demonstrating the possibility to
reduce cardiovascular risk. Human oxLDL-C are linked to
atherosclerosis, coronary heart disease, and coronary events
[54]. oxLDL-C can be bound by phenolic compounds present
in plasma, which have a peroxyl scavenging activity in the
arterial intima [55], and their concentrations decrease with
increased consumption of phenolic compounds. Further-
more, Briante et al. [56] demonstrated that HT exerts its anti-
oxidant eﬀects only at high concentrations. However, results
Table 5: Body composition parameters.
Parameter
Baseline (T0)
Mean± SD
(n = 28)
HTT
Mean± SD
(n = 28)
p
Baseline (T2)
Mean± SD
(n = 28)
PT
Mean± SD
(n = 28)
p
Weight (kg) 67.35± 9.77 67.04± 9.98 0.04∗ 66.74± 9.68 67.25± 9.91 0.52
BMI (kg/m2) 24.39± 3.39 24.27± 3.51 0.05 24.12± 3.33 24.37± 3.11 0.94
Waist circumference (cm) 77.24± 7.04 78.14± 6.93 0.16 76.78± 7.15 78.28± 9.07 0.09
Hip circumference (cm) 99.07± 7.67 98.92± 8.34 0.82 98.41± 7.92 99.21± 7.29 0.47
Waist/hip ratio 0.78± 0.07 0.79± 0.06 0.13 0.78± 0.06 0.78± 0.06 0.87
Biceps skinfold (mm) 5.99± 2.57 5.44± 2.57 0.07 5.57± 4.39 5.87± 2.49 0.13
Triceps skinfold (mm) 15.93± 6.36 14.83± 8.02 0.13 15.74± 7.16 16.01± 7.87 0.58
Subscapular skinfold (mm) 13.39± 3.89 12.89± 3.69 0.17 13.48± 4.65 14.26± 5.25 0.66
Suprailiac skinfold (mm) 12.38± 5.25 11.63± 5.13 0.01∗ 12.66± 6.01 12.60± 5.68 0.83
FM% (skinfolds) 24.30± 7.29 23.44± 7.96 0.01∗ 23.95± 7.14 23.73± 8.05 0.13
TBW (L) 38.03± 7.25 38.01± 7.43 0.98 37.11± 6.87 37.23± 6.99 0.06
ECW (L) 17.58± 8.35 16.62± 3.12 0.001∗ 16.75± 2.72 16.34± 2.88 0.02∗
ICW (L) 20.45± 4.91 21.39± 4.79 0.14 20.36± 4.66 20.18± 4.91 0.10
Phase angle 6.02± 0.72 6.46± 0.87 0.01∗ 6.51± 0.88 6.62± 0.85 0.02∗
All parameters were evaluated before and after HTT. All results are expressed as mean ± standard deviation (SD) (number of replicates = 3). Statistical
signiﬁcance attributed to results with ∗p < 0 05 (between HTT and baseline (T0) or between PT and baseline (T2)) after parametric test (Student t-test). PT:
placebo treatment; HTT: 15mg/day hydroxytyrosol treatment; BMI: body mass index; FM: fat mass; TBW: total body water; ECW: extracellular water;
ICW: intracellular water.
0
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Figure 2: Gene expression on baseline and after HTT. Diﬀerent levels of fold change of genes analyzed baseline (B) and HTT; ∗p < 0 05.
APOE: apolipoprotein E; MIF: macrophage migration inhibitory factor; SOD1: superoxide dismutase 1; PPARγ: peroxisome
proliferator-activated receptor gamma; ACE: angiotensin I-converting enzyme; MTFHR: methylenetetrahydrofolate reductase; CAT:
catalase; CCL2: chemokine (C-C motif) ligand 2; NFkB1: nuclear factor of kappa light polypeptide gene enhancer in B-cells 1.
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on direct correlations between oxLDL-C and phenolic com-
pound concentrations are conﬂicting [57]. In contrast to
other studies [16, 58, 59], in which it was reported that the
intake of EVOO, especially with the high content of
secoiridoidic derivatives, decreased the concentration of
oxLDL-C, TC, Tg, LDL, and LDL/TC ratio, we did not observe
any signiﬁcant change in these parameters after HTT. The
highlighted eﬀects of the other studies by may depend
on the simultaneous intake of diﬀerent EVOO polyphe-
nols, for a long period, while the amount present in the
pharmaceutical formulation used may not be suﬃcient to
modulate lipid proﬁle in 3 weeks treatment. Moreover,
previous studies [55, 59] have used HT concentrations
based on body weight, which result higher than the
amount administrated in this study. Therefore, our data
suggest a personalized dose of HT.
Conversely, a signiﬁcant increase of thiols and TAS
values, as well as the reduction of nitrite, nitrate, and MDA
concentrations, was shown in this study. In general, TAS is
a reﬂection of oxidative stress, and growing TAS concentra-
tion after HTT indicates that HT supplementation leads to
the improvement of oxidant activity. Thiols are organic com-
pounds that exist in vivo in three forms, which include the
free thiol, homodisulﬁdes, and heterodisulﬁdes, and they
are the most represented category of the total body antioxi-
dants, playing a pivotal role in defense against ROS [60]
representing a marker of CVDs, especially for atherosclerotic
plaque, thickness of intima-media, and vasodilatation of
endothelium [61]. The increased thiols concentration after
HTT could implicate a prominent role of the phenolic com-
pound in the maintenance of redox balance, probably due to
its antioxidant activity, which protects endogenous antioxi-
dant molecules from oxidation. At the same time, MDA con-
centration indicates the in vivo peroxidation of PUFAs and is
considered as an atherogenic factor per se [62]. In accordance
to Katsarou et al. [17], we noticed a signiﬁcant reduction of
MDA concentration after HTT, which enforce the idea that
HT is able to protect cells membrane and other molecules
from oxidation and to reduce the atherosclerosis risk. Fur-
thermore, a positive correlation between MDA and nitrite
concentrations was found at baseline (T0), while this was
not observed after HTT, proving that the antioxidant eﬀect
of HT prevents lipid oxidation. In contrast to González-
Santiago et al. [63], we did not notice signiﬁcant changing
neither on lipid proﬁle, except for LDL concentrations, nor
in plasma and erythrocyte membrane PUFAs, suggesting
that HT supplementation in healthy subjects, as expected,
does not exert any change in lipid proﬁle, which instead is
modulated by MUFAs contained in EVOO, in accordance
with Wahle et al. [7]. In healthy subjects, LDL-C concentra-
tions under 150mg/dL are considered normal values. The
increased LDL-C concentrations that we observed after
HTT and PT, although signiﬁcant, remain normal values
and, at the same time, determined the slight, and not
signiﬁcant, increase of TC observed after treatments, as
demonstrated by the positive correlation between TC and
LDL-C. Furthermore, the signiﬁcant increase of LDL-C
concentrations observed in both HTT and PT, making this
changing independent from the treatment. For all these
reasons, the increasing LDL-C concentration could be
not correlated to the increase of atherogenic risk.
Furthermore, this study suggests a pivotal role of HT in
the nitrite/nitrate management. In vivo and in vitro studies
observed that some EVOO compounds are able to exert
scavenging activity proprieties on peroxinitrites and nitrites
[27, 64]. Our data indicate that HT determines a critical
reduction of nitrite and nitrate concentrations in plasma.
The possible explanation of this eﬀect could be found in the
increasing expression of SOD1 related to HT supplementa-
tion, a hypothesis that is in line with Yao et al.’s results [20].
Moreover, at baseline, a signiﬁcant negative correlation
between SOD1 gene expression and the concentration of
circulating nitrites emerged. Since SOD1 decreases the
amount of peroxynitrites, we presume that HT caused
the reduction in this radical species, associated with the
increase of SOD1 expression. In fact, we did not observe
any correlation between SOD1 expression and nitrite con-
centration after HTT. As plasma nitrite concentration is a
marker of NO generation [65], and the reduction of NO
bioavailability is related to endothelial dysfunction, which
in turn is associated with the atherosclerosis and CVD
onset, our results suggest another possible mechanism
of action of HT in CVD prevention in accordance with
Zrelli et al. [66]. Furthermore, compared to a reduction
of circulating nitrite concentrations after HTT, it was
observed that HT bioavailability correlates positively with
nitrites (ρ = 0 94; p = 0 001), suggesting likely the scavenging
activity of HT on peroxinitrites, which in turn are commonly
transformed into nitrites [16, 67, 68]. All genomic and meta-
bolomics results reﬂect the high grade of bioavailability of
HT supplements.
These ﬁndings support the role of HT supplementation
in the gene-mediated eﬀects in correlation with the reduction
of biomarkers of oxidative stress and improved body compo-
sition, in the absence of a speciﬁc dietary regime.
Based on our results, the HT consumption of 15mg/die
would be advisable in relation to the reduction of oxida-
tive stress and reduction of cardiovascular risk due to
body composition, lipid, and plasma antioxidant proﬁle
improvement. Conversely, HT supplementation used in
our study, perhaps, is not suﬃcient to exert antioxidant
eﬀects on oxLDL-C.
Unfortunately, the limits of this study were the small
number of enrolled subjects and short duration of chronic
treatment. However, the calculated sample size has been
chosen regarding previous nutrigenomic studies in clinical
trials [69, 70]. Since, on the basis of literature results, it has
been demonstrated that a 6-week dietary treatment with
50mL/day of EVOO, which contains an average of 2mg/L
of HT, exerts a positive role on the lipid proﬁle [18], we con-
sidered a 3-week treatment period with 15mg/day of HT,
suﬃcient to assess the eﬃcacy of the treatment itself. Further-
more, a 3-week treatment period was chosen in order to
ensure complete adhesion of healthy volunteers to clinical
trial of 8 weeks of duration. However, according to our
results, 3 weeks of treatment is not suﬃcient to draw a ﬁrm
conclusion about HT eﬃcacy. A longer period with cycles
of two months of HTT could be helpful.
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5. Conclusion
In this work, we observed how 15mg/die of HT consumption
could exert positive eﬀects on human health reducing oxida-
tive stress and cardiovascular risk, and improving lipid and
plasma antioxidant proﬁle, although this daily amount of
HT does not seem to produce any positive eﬀects on
oxLDL-C. Set the minimum supplementation of 5mg/die of
HT recommended by EFSA, these results suggest a necessary
personalization of HT doses in order to exert its health ben-
eﬁts in CVD prevention and protection of LDL-C particles
from oxidative damage. However, further clinical trials are
needed on a larger population over a longer period to
increase knowledge about therapeutic mechanisms and
ensure its eﬃcacy and safety.
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